Abstract
Substantial advances in antigen-targeted lymphoma therapy have been achieved in recent years that make the use of monoclonal antibodies a highly attractive concept and promise further improvements in the clinical management of malignant lymphoma. The development of the chimeric anti-CD20 antibody IDEC-C2B8 (Rituximab) proved the concept of an effective therapy with a single unconjugated monoclonal antibody in lymphoma patients. Radioimmunoconjugates with myeloablative activity induced response rates of 80–100% in heavily pretreated patients. Progress in the genetic engineering of immunotoxins has improved the efficacy of these constructs. Ongoing prospective clinical trials will define the optimal use of these innovative therapeutic agents in patients with malignant lymphoma, and may establish therapeutic strategies with a high anti-lymphoma specificity and a low unspecific toxicity.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: June 2, 1999 / Accepted: August 16, 1999
Rights and permissions
About this article
Cite this article
Feuring-Buske, M., Buske, C., Unterhalt, M. et al. Recent advances in antigen-targeted therapy in non-Hodgkin's lymphoma. Ann Hematol 79, 167–174 (2000). https://doi.org/10.1007/s002770050575
Issue Date:
DOI: https://doi.org/10.1007/s002770050575